Jian Z Yu

US Patent:

7700339, Apr 20, 2010

Filed:

Apr 13, 2007

Appl. No.:

11/787132

Inventors:

Klarisa Rikova - Reading MA, US
Herbert Haack - Holliston MA, US
Laura Sullivan - Beverly MA, US
Ailan Guo - Burlington MA, US
Anthony Possemato - Framingham MA, US
Joan MacNeill - Derry NH, US
Jian Yu - Hamilton MA, US

Assignee:

Cell Signaling Technology, Inc. - Danvers MA

International Classification:

C12N 15/63
C12N 15/00
C12N 1/21
C12N 5/10
C12P 21/00
C12Q 1/68
C07H 21/00
C12N 9/12
C12Q 1/48
C07K 14/00

US Classification:

435194, 4353201, 4352523, 435325, 435 691, 435 6, 435 15, 435455, 435471, 530350, 536 232, 536 234, 536 235

Abstract:

In accordance with the invention, novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e. g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ALK kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of this new fusion protein enables new methods for determining the presence of these mutant ALK kinase polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention.

US Patent:

7977462, Jul 12, 2011

Filed:

Apr 18, 2008

Appl. No.:

12/148547

Inventors:

Peter Hornbeck - Magnolia MA, US
Ailan Guo - Burlington MA, US
Klarisa Rikova - Reading MA, US
Albrecht Moritz - Salem MA, US
Charles Farnsworth - Concord MA, US
Matthew Stokes - Beverly MA, US
Jian Yu - Hamilton MA, US
Erik Spek - Cambridge MA, US
Yu Li - Andover MA, US
Anthony Possemato - Framingham MA, US
Jessica Cherry - Durham NH, US
Valerie Goss - Seabrook NH, US
Jeffrey Mitchell - Nashua NH, US
John Rush - Beverly MA, US
Corinne Michaud - Salem MA, US

Assignee:

Cell Signaling Technology, Inc. - Danvers MA

International Classification:

C07K 16/00
C12P 21/08

US Classification:

5303871, 5303877, 5303879, 5303881, 5303888, 53038885, 5303891, 5303897

Abstract:

The invention discloses 482 novel phosphorylation sites identified in carcinoma and/or leukemia, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above.

US Patent:

8168383, May 1, 2012

Filed:

Oct 19, 2009

Appl. No.:

12/589176

Inventors:

Klarisa Rikova - Reading MA, US
Herbert Haack - South Hamilton MA, US
Laura Sullivan - Shrewsbury MA, US
Ailan Guo - Lexington MA, US
Anthony Possemato - Worcester MA, US
Joan MacNeill - Litchfield NH, US
Jian Yu - Hamilton MA, US

Assignee:

Cell Signaling Technology, Inc. - Danvers MA

International Classification:

C12Q 1/68
C12Q 1/48
C07H 21/00
C12N 9/12

US Classification:

435 61, 435194, 435 15, 536 231, 536 232, 536 235

Abstract:

Novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e. g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant polypeptides, probes for detecting it, isolated mutant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The invention also provides methods for determining the presence of these mutant polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides.

US Patent:

8288102, Oct 16, 2012

Filed:

Feb 27, 2010

Appl. No.:

12/714457

Inventors:

Klarisa Rikova - Reading MA, US
Herbert Haack - Holliston MA, US
Laura Sullivan - Beverly MA, US
Ailan Guo - Burlington MA, US
Anthony Possemato - Framingham MA, US
Joan MacNeill - Derry NH, US
Jian Yu - Hamilton MA, US

Assignee:

Cell Signaling Technology, Inc. - Danvers MA

International Classification:

C12Q 1/68
C12N 9/12
C07H 21/00

US Classification:

435 612, 435 61, 435194, 536 234, 536 243

Abstract:

In accordance with the invention, novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e. g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ALK kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of this new fusion protein enables new methods for determining the presence of these mutant ALK kinase polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention.

US Patent:

8377642, Feb 19, 2013

Filed:

Sep 28, 2010

Appl. No.:

12/891987

Inventors:

Klarisa Rikova - Reading MA, US
Herbert Haack - South Hamilton MA, US
Laura Sullivan - Beverly MA, US
Ailan Guo - Lexington MA, US
Anthony Possemato - Worcester MA, US
Joan MacNeill - Litchfield NH, US
Jian Yu - Hamilton MA, US

Assignee:

Cell Signaling Technology, Inc. - Danvers MA

International Classification:

C12Q 1/68
C07H 21/00
C12N 9/12

US Classification:

435 618, 435 614, 435 612, 435 611, 435194, 536 231, 536 232

Abstract:

In accordance with the invention, novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e. g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ALK kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of this new fusion protein enables new methods for determining the presence of these mutant ALK kinase polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention.

US Patent:

8481279, Jul 9, 2013

Filed:

Feb 6, 2012

Appl. No.:

13/366679

Inventors:

Klarisa Rikova - Reading MA, US
Herbert Haack - South Hamilton MA, US
Laura Sullivan - Shrewsbury MA, US
Ailan Guo - Lexington MA, US
Anthony Possemato - Worcester MA, US
Joan MacNeill - Litchfield NH, US
Jian Yu - Hamilton MA, US

Assignee:

Cell Signaling Technology, Inc. - Danvers MA

International Classification:

C12Q 1/48
A61K 31/00
C12N 9/12

US Classification:

435 15, 435194, 514 1

Abstract:

In accordance with the invention, novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e. g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ALK kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of this new fusion protein enables methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides.

US Patent:

8486645, Jul 16, 2013

Filed:

Apr 3, 2012

Appl. No.:

13/438218

Inventors:

Klarisa Rikova - Reading MA, US
Herbert Haack - South Hamilton MA, US
Laura Sullivan - Shrewsbury MA, US
Ailan Guo - Lexington MA, US
Anthony Possemato - Worcester MA, US
Joan MacNeill - Litchfield NH, US
Jian Yu - Hamilton MA, US

Assignee:

Cell Signaling Technology, Inc. - Danvers MA

International Classification:

G01N 33/53
G01N 33/563
C12Q 1/48
C12N 9/12
G01N 35/08

US Classification:

435 71, 435 15, 435194, 436512, 436513, 436 52

Abstract:

Novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e. g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant polypeptides, probes for detecting it, isolated mutant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The invention also provides methods for determining the presence of these mutant polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides.

US Patent:

20060213829, Sep 28, 2006

Filed:

Mar 25, 2005

Appl. No.:

11/089931

Inventors:

Gregory Rutledge - Newton MA, US
Jian Yu - Cambridge MA, US
Sergey Fridrikh - Acton MA, US

International Classification:

B01D 24/00
B01D 39/00

US Classification:

210503000, 210505000, 264041000

Abstract:

Electrospinning of materials that are difficult or impossible to process into nanofibers by conventional fiber-forming techniques or by electrospinning are prepared by an electrospinning procedure which uses an electrospinnable outer “shell” fluid around an inner “core” fluid, which may or may not be electrospinnable, to form nanofibers of the inner core fluid having a core/shell morphology. The resulting shell around the nanofiber can remain in place or be removed during post-processing with the core of the fiber remaining intact. The dual-fluid electrospinning process can produce core fibers having diameters less than 100 nm, insulated nanowires, as well as tough, bio-compatible silk fibers. Alternatively, the core can be removed leaving a hollow fiber of the shell fluid.